Ultragenyx Pharmaceutical Inc. buy marge
Start price
19.04.17
/
50%
€58.68
Target price
20.07.17
€63.14
Performance (%)
7.76%
End price
20.07.17
€63.23
Summary
This prediction ended on 20.07.17 with a price of €63.23. With a performance of 7.76%, the BUY prediction by marge for Ultragenyx Pharmaceutical Inc. closed with a slight gain. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.608% | -3.608% | -47.765% | -51.302% |
| iShares Core DAX® | -0,68 % | -4,85 % | 1,94 % | 54,33 % |
| iShares Nasdaq 100 | -0,03 % | 2,86 % | 18,90 % | 82,62 % |
| iShares Nikkei 225® | -0,54 % | -5,02 % | 28,15 % | 55,64 % |
| iShares S&P 500 | -0,21 % | 0,92 % | 13,69 % | 61,21 % |
Comments by marge for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical m. Tradingchance on positive results for hypophosphatemia drug test
Ultragenyx Pharmaceutical (NASDAQ:RARE) +19.8% AH on news that its burosumab drug to treat x-linked hypophosphatemia, a genetic kidney disorder, met its primary endpoint in a phase 3 study.
RARE says patients treated with the drug showed a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels vs. 8% on placebo.